Important note

This AI stock analysis for C4 Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

C4 Therapeutics - AI Stock Analysis

Analysis generated October 9, 2025

Founded in 2016, C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company focused on developing novel therapies to harness the body's natural mechanisms for targeted protein degradation. By leveraging their proprietary platform, known as TORPEDO (Target ORiented Protein Degrader), C4 Therapeutics aims to develop treatments for a variety of difficult-to-treat diseases, including cancer.

Fundamental Analysis

The most recent financial metrics for C4 Therapeutics show a mixed performance.

Revenue: The company reported revenue of $6.5 million for the last quarter, representing a decrease of 10.71% compared to the previous quarter and a 46.17% decrease from the same quarter last year. These figures indicate potential challenges in revenue generation, which may require strategic adjustments.

Net Income: The net income for the last quarter was $26 million, marking a 1.15% increase from the prior quarter, signifying slight growth. However, compared to the same quarter last year, net income dropped by 46.87%, signaling potential difficulties in maintaining profitability.

EBITDA: EBITDA for the last quarter was reported at $29 million, a slight 0.72% increase from the previous quarter. Nonetheless, this represents a significant 81.87% decline from the same quarter last year, further pointing to challenges in operational efficiencies.

Technical Analysis

The current stock price of C4 Therapeutics stands at $2.41.

This reflects a 10.07% decrease over the past month, raising short-term concerns. Over a longer term, the stock has seen a 54.53% decline over the past year, which could be troubling for long-term investors. Despite these concerns, the overall trend appears to be bullish. The current Simple Moving Average (SMA10) is $2.26, compared to the previous SMA10 of $2.24, indicating a potential upward trend in price movement. The Relative Strength Index (RSI) of 61.8 signifies a neutral condition, not overbought nor oversold.

Alternative Data Analysis

Analyzing alternative data provides additional insights into the company's outlook.

Job Postings and Employee Sentiment: C4 Therapeutics has consistently maintained 1 open position over the last few months, indicating stability and a potential for near-term growth. The employee sentiment is neutral, which speaks to a balanced internal outlook on the company’s future.

Customer Acquisition: The company's website attracts an estimated 5,000 visitors monthly, with no significant change recently. This stability suggests steady interest in the company's offerings and developments.

Customer Engagement: On social media, C4 Therapeutics boasts 1,800 Twitter followers, marking a 3% increase in recent months. This signals growing interest and engagement with the company’s updates and activities.

AI-Based Analysis: According to AltIndex, which uses various metrics to predict stock price movement, C4 Therapeutics holds an AI score of 54. This score indicates a hold signal, suggesting neither a strong buy or sell signal currently.

Conclusion

C4 Therapeutics presents a mixed bag of opportunities and challenges. From a fundamental perspective, the company has seen declines in revenue and EBITDA compared to last year, while net income shows modest short-term growth. In terms of technical analysis, despite recent dips in stock price, some bullish signs indicate potential upward trends. The alternative data analysis highlights stability with employee sentiment, steady website traffic, and growing social media engagement, adding to the nuanced outlook.

Based on the analysis, the recommendation is to hold the stock. The company's potential for innovation in protein degradation therapies and steady alternative data indicators suggest room for future growth, albeit with caution due to the recent financial volatility.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.